Your Web News in One Place

Help Webnuz

Referal links:

Sign up for GreenGeeks web hosting
July 17, 2018 10:00 am

China Negotiating For Cheaper Cancer Drugs

hackingbear writes: "China's medical insurance regulator will begin negotiations with domestic and overseas pharmaceutical companies to lower prices of cancer drugs in a bid to cut the financial burden on patients," reports Reuters. "The State Medical Insurance Administration said it was preparing to include more cancer drugs on its list of medicines eligible for reimbursement, and said 10 foreign and eight domestic pharmaceutical companies had expressed a willingness to work with the authority." Unlike India, or what we may have been told, China enforces pharmaceutical patents rigorously. Recently, the Chinese box office hit Dying to Survive, which told the real life story of a leukemia patient/businessman put on trial due to smuggling imitation drugs to help fellow patients who cannot pay the exorbitant cost of a drug produced by a Swiss pharmaceutical giant, has brought in huge revenues and rave reviews since the movie was released on July 5. Last year, China forced two rounds of NRDL negotiations after seven years of stasis. More than a dozen cancer drugs, including AstraZeneca's Iressa and Roche's Herceptin, are now covered by the country's insurance program, but only after the companies agreed to huge discounts -- a typical move trading lower prices for higher volume. Demand for Herceptin, for example, surged after the discount and triggered a national shortage.

Read more of this story at Slashdot.


Original Link: http://rss.slashdot.org/~r/Slashdot/slashdot/~3/cQxakxKgz6o/china-negotiating-for-cheaper-cancer-drugs

Share this article:    Share on Facebook
View Full Article

Slashdot

Slashdot was originally created in September of 1997 by Rob "CmdrTaco" Malda. Today it is owned by Geeknet, Inc..

More About this Source Visit Slashdot